Drug & Cancer & Variant
Result
Search content: Gene = ARAF
There are 9 entries with your keyword(s).
Gene Variant Type Tumor Drug Drug level Reference More
ARAF Oncogenic Mutations MUT Colon Cancer BRAF inhibitors+EGFR mAb inhibitors RII 1
Evidence region

CGI

Patient Criteria

-

Note

-

Gene name

ARAF

Full name

A-Raf proto-oncogene, serine/threonine kinase

Gene type

protein-coding

Function

This proto-oncogene belongs to the RAF subfamily of the Ser/Thr protein kinase family, and maybe involved in cell growth and development. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Jan 2012]

Sorry, there is no related drug information.

ARAF Oncogenic Mutations MUT Colon Cancer BRAF inhibitors+MEK inhibitors RII 1
Evidence region

CGI

Patient Criteria

-

Note

-

Gene name

ARAF

Full name

A-Raf proto-oncogene, serine/threonine kinase

Gene type

protein-coding

Function

This proto-oncogene belongs to the RAF subfamily of the Ser/Thr protein kinase family, and maybe involved in cell growth and development. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Jan 2012]

Sorry, there is no related drug information.

ARAF Oncogenic Mutations MUT Histiocytosis Cobimetinib II 2
Evidence region

OncoKB

Patient Criteria

-

Note

-

Gene name

ARAF

Full name

A-Raf proto-oncogene, serine/threonine kinase

Gene type

protein-coding

Function

This proto-oncogene belongs to the RAF subfamily of the Ser/Thr protein kinase family, and maybe involved in cell growth and development. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Jan 2012]

Drug name

Cobimetinib

DrugBank ID

DB05239

Synonyms

Cobimetinib

Brand

Cotellic

Description

Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma.

Target gene
GeneFunction
MAP2K1inhibitor
ARAF Oncogenic Mutations MUT Histiocytosis Sorafenib II 2
Evidence region

OncoKB

Patient Criteria

-

Note

-

Gene name

ARAF

Full name

A-Raf proto-oncogene, serine/threonine kinase

Gene type

protein-coding

Function

This proto-oncogene belongs to the RAF subfamily of the Ser/Thr protein kinase family, and maybe involved in cell growth and development. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Jan 2012]

Drug name

Sorafenib

DrugBank ID

DB00398

Synonyms

4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
Sorafénib
Sorafenib
Sorafenibum

Brand

Nexavar

Description

Sorafenib (rINN), marketed as Nexavar by Bayer, is a drug approved for the treatment of advanced renal cell carcinoma (primary kidney cancer). It has also received "Fast Track" designation by the FDA for the treatment of advanced hepatocellular carcinoma (primary liver cancer), and has since performed well in Phase III trials. Sorafenib is a small molecular inhibitor of Raf kinase, PDGF (platelet-derived growth factor), VEGF receptor 2 & 3 kinases and c Kit the receptor for Stem cell factor. A growing number of drugs target most of these pathways. The originality of Sorafenib lays in its simultaneous targeting of the Raf/Mek/Erk pathway.

Target gene
GeneFunction
BRAFinhibitor
RAF1inhibitor
FLT4antagonist
KDRantagonist
FLT3antagonist
PDGFRBantagonist
KITantagonist
FGFR1inhibitor
RETinhibitor
FLT1inhibitor
ARAF Oncogenic Mutations MUT Non-Small Cell Lung Cancer Sorafenib II 1
Evidence region

OncoKB

Patient Criteria

-

Note

The ARAF mutations were shown to transform immortalized human airway epithelial cells in a sorafenib-sensitive manner. These results suggest that mutant ARAF is an oncogenic driver in lung adenocarcinoma and an indicator of sorafenib response.

Gene name

ARAF

Full name

A-Raf proto-oncogene, serine/threonine kinase

Gene type

protein-coding

Function

This proto-oncogene belongs to the RAF subfamily of the Ser/Thr protein kinase family, and maybe involved in cell growth and development. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Jan 2012]

Drug name

Sorafenib

DrugBank ID

DB00398

Synonyms

4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
Sorafénib
Sorafenib
Sorafenibum

Brand

Nexavar

Description

Sorafenib (rINN), marketed as Nexavar by Bayer, is a drug approved for the treatment of advanced renal cell carcinoma (primary kidney cancer). It has also received "Fast Track" designation by the FDA for the treatment of advanced hepatocellular carcinoma (primary liver cancer), and has since performed well in Phase III trials. Sorafenib is a small molecular inhibitor of Raf kinase, PDGF (platelet-derived growth factor), VEGF receptor 2 & 3 kinases and c Kit the receptor for Stem cell factor. A growing number of drugs target most of these pathways. The originality of Sorafenib lays in its simultaneous targeting of the Raf/Mek/Erk pathway.

Target gene
GeneFunction
BRAFinhibitor
RAF1inhibitor
FLT4antagonist
KDRantagonist
FLT3antagonist
PDGFRBantagonist
KITantagonist
FGFR1inhibitor
RETinhibitor
FLT1inhibitor
ARAF S214C MUT Lung Adenocarcinoma Sorafenib IV 2
Evidence region

CGI

Patient Criteria

-

Note

The ARAF mutations were shown to transform immortalized human airway epithelial cells in a sorafenib-sensitive manner. These results suggest that mutant ARAF is an oncogenic driver in lung adenocarcinoma and an indicator of sorafenib response.

Gene name

ARAF

Full name

A-Raf proto-oncogene, serine/threonine kinase

Gene type

protein-coding

Function

This proto-oncogene belongs to the RAF subfamily of the Ser/Thr protein kinase family, and maybe involved in cell growth and development. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Jan 2012]

Drug name

Sorafenib

DrugBank ID

DB00398

Synonyms

4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
Sorafénib
Sorafenib
Sorafenibum

Brand

Nexavar

Description

Sorafenib (rINN), marketed as Nexavar by Bayer, is a drug approved for the treatment of advanced renal cell carcinoma (primary kidney cancer). It has also received "Fast Track" designation by the FDA for the treatment of advanced hepatocellular carcinoma (primary liver cancer), and has since performed well in Phase III trials. Sorafenib is a small molecular inhibitor of Raf kinase, PDGF (platelet-derived growth factor), VEGF receptor 2 & 3 kinases and c Kit the receptor for Stem cell factor. A growing number of drugs target most of these pathways. The originality of Sorafenib lays in its simultaneous targeting of the Raf/Mek/Erk pathway.

Target gene
GeneFunction
BRAFinhibitor
RAF1inhibitor
FLT4antagonist
KDRantagonist
FLT3antagonist
PDGFRBantagonist
KITantagonist
FGFR1inhibitor
RETinhibitor
FLT1inhibitor
ARAF S214C MUT Non-Small Cell Lung Cancer Sorafenib V 1
Evidence region

CIVIC

Patient Criteria

-

Note

Sorafenib can inhibit ARF-mediated MEK phosphorylation and soft agar colony formation of AALE cells expressing ARAF S214C in vitro.

Gene name

ARAF

Full name

A-Raf proto-oncogene, serine/threonine kinase

Gene type

protein-coding

Function

This proto-oncogene belongs to the RAF subfamily of the Ser/Thr protein kinase family, and maybe involved in cell growth and development. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Jan 2012]

Drug name

Sorafenib

DrugBank ID

DB00398

Synonyms

4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
Sorafénib
Sorafenib
Sorafenibum

Brand

Nexavar

Description

Sorafenib (rINN), marketed as Nexavar by Bayer, is a drug approved for the treatment of advanced renal cell carcinoma (primary kidney cancer). It has also received "Fast Track" designation by the FDA for the treatment of advanced hepatocellular carcinoma (primary liver cancer), and has since performed well in Phase III trials. Sorafenib is a small molecular inhibitor of Raf kinase, PDGF (platelet-derived growth factor), VEGF receptor 2 & 3 kinases and c Kit the receptor for Stem cell factor. A growing number of drugs target most of these pathways. The originality of Sorafenib lays in its simultaneous targeting of the Raf/Mek/Erk pathway.

Target gene
GeneFunction
BRAFinhibitor
RAF1inhibitor
FLT4antagonist
KDRantagonist
FLT3antagonist
PDGFRBantagonist
KITantagonist
FGFR1inhibitor
RETinhibitor
FLT1inhibitor
ARAF S214C MUT Non-Small Cell Lung Cancer Trametinib V 1
Evidence region

CIVIC

Patient Criteria

-

Note

Trametinib can inhibit ARF-mediated ERK phosphorylation and soft agar colony formation of AALE cells expressing ARAF S214C in vitro.

Gene name

ARAF

Full name

A-Raf proto-oncogene, serine/threonine kinase

Gene type

protein-coding

Function

This proto-oncogene belongs to the RAF subfamily of the Ser/Thr protein kinase family, and maybe involved in cell growth and development. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Jan 2012]

Drug name

Trametinib

DrugBank ID

DB08911

Synonyms

Tramétinib
Trametinib
Trametinibum

Brand

Mekinist

Description

Trametinib dimethyl sulfoxide is a kinase inhibitor. Each 1-mg tablet contains 1.127 mg trametinib dimethyl sulfoxide equivalent to 1 mg of trametinib non-solvated parent. FDA approved on May 29, 2013 [L2727]. The U.S. Food and Drug Administration approved [DB08912](Tafilnar) and Mekinist (trametinib), administered together, for the treatment of anaplastic thyroid cancer (ATC) that cannot be removed by surgery or has spread to other parts of the body (metastatic), and has a type of abnormal gene, BRAF V600E (BRAF V600E mutation-positive) [L2726]. Thyroid cancer is a disease in which cancer cells form in the tissues of the thyroid. Anaplastic thyroid cancer is a rare, aggressive type of thyroid cancer. The National Institutes of Health (NIH) estimates there will be 53,990 new cases of thyroid cancer and an estimated 2,060 deaths from the disease in the United States in 2018. Anaplastic thyroid cancer accounts for approximately 1 to 2 percent of all thyroid cancers [L2726].

Target gene
GeneFunction
MAP2K1antagonist
MAP2K2antagonist
ARAF S490T MUT Colon Cancer Irinotecan+Vemurafenib+Cetuximab RII 1
Evidence region

CIVIC

Patient Criteria

-

Note

Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 BRAF V600E mutant colorectal cancer patients. cfDNA panel sequencing was performed in 10 patients after disease progression. One patient had an acquired ARAF S490T mutation that was not identified before treatment initiation.

Gene name

ARAF

Full name

A-Raf proto-oncogene, serine/threonine kinase

Gene type

protein-coding

Function

This proto-oncogene belongs to the RAF subfamily of the Ser/Thr protein kinase family, and maybe involved in cell growth and development. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Jan 2012]

Drug name

Irinotecan

DrugBank ID

DB00762

Synonyms

(+)-Irinotecan
Irinotecan
Irinotecan lactone
Irinotecanum

Brand

Camptosar
Irinotecan Hydrochloride
Irinotecan hydrochloride
Onivyde
Irinotecan
Irinotecan Hydrochloride 100 mg/ 5 mL
Irinotecan hydrochloide
Irinotecan Hydrochloride 40 mg/2 mL
Irinotecan Hydrochloride Injection USP
Irinotecan Hydrochloride Injection
Onivyde Pegylated Liposomal
Irinotecan Hydrochloride 100 mg/5 mL
Irinotecan Hydrochloride Injection, USP
Irinotecan Hydrochloride Trihydrate for Injection
Irinotecan for Injection
Irinotecan Hydrochloride Trihydrate Injection

Description

Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).

Target gene
GeneFunction
TOP1inhibitor
TOP1MTinhibitor

Drug name

Vemurafenib

DrugBank ID

DB08881

Synonyms

Vémurafénib
Vemurafenib
Vemurafenibum

Brand

Zelboraf

Description

Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E.[A31269] It exerts its function by binding to the ATP-binding domain of the mutant BRAF.[A31270] Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program. [L1012]

Target gene
GeneFunction
BRAFinhibitor

Drug name

Cetuximab

DrugBank ID

DB00002

Synonyms

Cetuximab
Cétuximab
Cetuximabum

Brand

Erbitux

Description

Cetuximab is an epidermal growth factor receptor binding FAB. Cetuximab is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFr monoclonal antibody specific for the N-terminal portion of human EGFr with human IgG1 heavy and kappa light chain constant (framework) regions. Cetuximab is marketed under the brand Erbitux® by Eli Lilly and Company. In the United States, a regimen of cetuximab costs approximately $30,790 for an eight-week course.

Target gene
GeneFunction
EGFRantagonist
FCGR3BUnknown
C1QAUnknown
C1QBUnknown
C1QCUnknown
FCGR3AUnknown
FCGR1AUnknown
FCGR2AUnknown
Showing 1 to 9 of 9 entries, entries per page